Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 8/20 | 0.68 |
| ▸ | SELE | P16581 | 7/20 | 0.68 |
| ▸ | SELL | P14151 | 7/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | TOP2A | P11388 | 2/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13422091 | 0.85 | MEN1 (0.59) | SELPSELESELLMAPT | |
| SCHEMBL10316412 | 0.85 | SELP (0.70) | SELPSELESELLGAAMAPT | |
| SCHEMBL2003074 | 0.81 | MAPT (0.77) | GAAMAPTHTTHDAC1POLB | |
| SCHEMBL14015957 | 0.81 | SELP (1.00) | SELPSELESELLHDAC1HDAC3 | |
| SCHEMBL4665176 | 0.80 | SELP (0.65) | SELPSELESELLGAAMAPT | |
| SCHEMBL14015955 | 0.80 | SELP (1.00) | SELPSELESELL | |
| SCHEMBL7566765 | 0.78 | MAPT (0.77) | GAAMAPTHTTHDAC1POLB | |
| SCHEMBL10954256 | 0.78 | MEN1 (0.59) | GAAMAPTHTTHDAC1POLB | |
| SCHEMBL10953379 | 0.78 | HDAC1 (0.62) | GAAMAPTHTTHDAC1POLB | |
| SCHEMBL27160281 | 0.78 | NPY5R (0.77) | GAAMAPTHTTHDAC1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| EP-1732882-B1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-1732882-B1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-10-09 | — | — | US | disclosed |
| EP-1732882-A1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Revotar Biopharmaceuticals AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090284-A1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249107-A1 | Non-Glycosylated/Non-Glycosidic/Non-Peptidic Small Molecule Psgl-1 Mimetics for the Treatment of Inflammatory Disorders | SELP, SELPLG, SELE | SELP 1/4885SELE 3/4885SELL 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.